Scientists from the University of Cambridge have found that alemtuzumab, a drug originally developed for leukemia can curb the progression of multiple sclerosis (MS) even reverse some damage caused by the neurological disorder. The drug, a monoclonal antibody, has also been tested for treatment of other immune system disorders. Alemtuzumab targets the cells of the immune system that attack the myelin sheath and the nerve fibers.